Overview

Overview

In this section you can find all materials related to our financial reporting

Latest Annual Report (20-F)

Latest Annual Report (German)

BioNTech Geschaeftsbericht 2019

Latest Quarterly Report

Show all

Latest SEC Filings

Filing date Description Form View

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

 6-K View HTML
0001564590-20-031413.pdf
0001564590-20-031413.rtf
0001564590-20-031413.xls

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

 6-K View HTML
0001564590-20-030913.pdf
0001564590-20-030913.rtf
0001564590-20-030913.xls

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

 6-K View HTML
0001564590-20-030780.pdf
0001564590-20-030780.rtf
0001564590-20-030780.xls

Toolkit

Media Contact Jasmina Alatovic
Senior Manager Global External Communications
Media@biontech.de
+49 6131 9084-1513
Investor Contact Sylke Maas, Ph.D.
VP Investor Relations & Business Strategy
Investors@biontech.de
+49 6131 9084-074
For U.S. Investors:
Westwicke
Victoria Meissner, M.D.
victoria.meissner@westwicke.com
+1 646 677-1837
Whistleblower Hotline BioNTech Hotline (anonymous)
Germany: 0800 000-8972
US: 844 901-0271
Other: +1 757 278-0107
Online Access to Whistle Blowing Reporting
Or by Email